Sheel Biotech IPO Allotment Status: Subscription & How to Verify

IPO Overview & Subscription Figures

Here’s what is known about the Sheel Biotech IPO:

  • IPO Type: SME / Book‑building
  • Issue Open Date: 30 September 2025
  • Issue Close Date: 3 October 2025
  • Price Band: ₹ 59 to ₹ 63 per share
  • Lot Size: 2,000 shares
  • Issue Size: ~ ₹ 34.02 crore
  • Registrar: Skyline Financial Services Pvt. Ltd.
  • Allotment Date: 6 October 2025
  • Refund / Share Credit Date: 7 October 2025
  • Listing Date: 8 October 2025
  • Quota / Reservation: Retail ~ 35%, NII ~ 15%, QIB ~ 50%

Subscription / Demand Data

  • At one snapshot, the IPO was 0.34× subscribed overall — meaning demand was less than supply. In that snapshot:
    • Retail subscription ~ 0.69×
    • NII subscription ~ 0.66×
    • QIB subscription ~ 0.01×
  • During early subscription days, the demand was particularly low. For example, on Day 1 the total subscription was ~ 0.07× across categories.
  • Because it’s undersubscribed in many categories, many retail investors may receive full allotment (or improved odds) depending on how allocations are handled.

Key Dates to Watch

EventDate
IPO Open30 September 2025
IPO Close3 October 2025
Basis of Allotment / Allotment Declaration6 October 2025
Refund Initiation / Shares Credited7 October 2025
Listing Date8 October 2025

How to Check Sheel Biotech IPO Allotment Status Online

Here are reliable methods you can use to verify your allotment:

Method 1: Registrar’s Website (Skyline Financial Services)

  1. Go to the Skyline Financial IPO / allotment status page.
  2. In the dropdown or issuer list, select Sheel Biotech IPO.
  3. Enter your PAN, Application Number, or DP / Demat Client ID (depending on what the site allows).
  4. Enter captcha or any required verification.
  5. Click Search / Submit.
  6. The result will show how many shares you applied for vs how many you were allotted (if any).

Method 2: Stock Exchange Portal (BSE / NSE SME Allotment)

  • Visit BSE’s “IPO / Application Status / Allotment” page.
  • Select Equity / SME as the issue type.
  • Pick Sheel Biotech IPO from the issue list.
  • Enter your PAN / Application Number / DP ID.
  • Submit and view the allotment status.
  • (If applicable) use the NSE SME portal similarly.

Method 3: Through Broker / Demat / Trading Account

  • Log into your broker/trading app (Zerodha, Upstox, Angel, etc.).
  • Go to the IPO / Investments or Order / Applications section.
  • After allotment, some brokers will show “Allocated / Not Allocated / Partial” status.
  • If shares are allotted, you should see them in your Demat holdings after the credit date (7 Oct).
  • If not allotted, a refund or release of blocked funds should reflect in your bank account the same day (7 Oct).

What to Expect After Allotment

  • Because the IPO is undersubscribed in many segments, there’s a decent chance that many retail applicants may receive full allotment (or at least better odds).
  • If allotted, shares will be credited to your Demat account on or by the refund/share credit date (7 October).
  • If not allotted or partially allotted, your excess application amount will be refunded automatically.
  • In case your shares or refund do not reflect on the expected date, contact the registrar (Skyline) or your broker with your application details (PAN, application number, etc.).

Disclaimer

The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.